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Primary hyperparathyroidism may occur as a part of an inherited syndrome in a combination with pancreatic endocrine tumours
and/or pituitary adenoma, which is classiﬁed as Multiple Endocrine Neoplasia type 1 (MEN-1). This syndrome is caused by
a germline mutation in MEN-1 gene encoding a tumour-suppressor protein, menin. Primary hyperparathyroidism is the most
frequent clinical presentation of MEN-1, which usually appears in the second decade of life as an asymptomatic hypercalcemia and
progressesthroughthenextdecades.ThemostfrequentclinicalpresentationofMEN-1-associatedprimaryhyperparathyroidismis
bonedemineralisationandrecurrentkidneystonesrarelyfollowedbychronickidneydisease.Theaimofthispaperistopresentthe
pathomechanism, screening procedures, diagnosis, and management of primary hyperparathyroidism in the MEN-1 syndrome.
It also summarises the recent advances in the pharmacological therapy with a new group of drugs—calcimimetics.
1.Introduction
Primary hyperparathyroidism is rarely a part of multiple
endocrine neoplasia type 1 (MEN-1) syndrome with familial
occurrence. The genetic background of this syndrome oﬀers
a unique opportunity to review a pathomechanism of
tumourigenesis that may be also operative in some sporadic
tumours.
The classic clinical manifestation of MEN-1 is a com-
position of parathyroid hyperplasia, pancreatic endocrine
tumour, and pituitary adenoma [1]. All three tumours,
however, do not develop in all aﬀected patients during their
life span. Therefore, the contemporary deﬁnition of MEN-1
is the coincidence of at least two of the above-mentioned
tumours [1]. A diagnosis of familial MEN-1 requires, besides
that, a ﬁrst-degree relative with at least one of the three
tumours [1].
In an autopsy series, prevalence of the MEN-1 syndrome
was estimated at 2.2 per 1000 in the general population [2],
but biochemical surveys suggested lower ﬁgures—0.01–
0.175per1000[3,4].Inpatientswithprimaryhyperparathy-
roidism (HPT) approximately 1–5% is associated with the
MEN-1 syndrome [3, 5]. Combining this data with HPT
incidence, the prevalence of MEN-1 can be estimated to be
10–30 per 100,000 in the general population.
In about 60% of MEN-1 patients enteropancreatic
tumoursarefound.Mostofthemaresmallandnonsecreting.
The most common hormonally active ones are insulinomas
and gastrinomas. Opposite to parathyroid tumours MEN-1-
associated gastrinomas are typically multiple, often malig-
nant [6]. Moreover, it is important to stress that other
enteropancreatic tumours usually accompany gastrinoma in
MEN-1 [7]. Insulinoma is found in 10–30% of MEN-1 cases
withtheclassicclinicalpresentationwithrecurrentneurogly-
copenia, mainly in fasting, similar to that of sporadic cases.
Other rare enteropancreatic tumours diagnosed in MEN-1
may secrete somatostatin, glucagon, vasoactive intestinal
peptide (VIP), growth hormone-releasing factor (GHRH),2 International Journal of Endocrinology
ACTH, or parathyroid hormone-related peptide (PTHrP)
[8].
In approximately 30% of MEN-1 patients prolactin-
secreting microadenomas or “nonfunctional” adenomas are
found in the pituitary gland [9, 10]. Tumours secreting
growth hormone or ACTH are less frequent, with the signs
and symptoms equivalent to those in sporadic cases.
Neuroendocrine tumour (carcinoid), found in about
14% of MEN-1 cases, originates mainly from the foregut
(thymus, bronchus, stomach, pancreas, duodenum) [11], in
contrast to sporadic cases originating mainly from midgut
[12]. In up to 40% of MEN-1 cases nonfunctional adrenal
cortical enlargement has been found by radiological imaging
[13].
The localization of the tumours in the MEN-1 syndrome
cannot be explained by the ubiquitous expression pattern of
the mutated gene MEN-1 and its encoded protein, menin.
The interaction of menin with mixed-lineage leukaemia
protein-containing histone methyl transferase (MLL-HMT)
complex mediates tissue-selective tumour-suppressing and
tumour-promoting eﬀects and may be responsible for the
tissue susceptibility to tumourigenesis in MEN-1 [14].
2. MEN-1 GeneFunction
T h eM E N - 1g e n ei s9 . 8 k bi n1 0e x o n sl o c a t e do nc h r o -
mosome 11q13 and encodes a 610-amino acid 67-kDa
proteinmenin [15].Meninisubiquitouslyexpressed,located
primarily in the nucleus [16] and is able to bind to the
DNA independently of the sequence [17]. In meiosis it
colocalizeswithtelomeres[18].Meninisabletobinddirectly
or indirectly to the proteins regulating transcription, DNA
processing, or DNA repair as well as cytoskeleton-associated
proteins [19–21].
Although its exact role is not fully understood, menin
acts as a tumour suppressor. It is suggested that in cells
lacking menin DNA damage is increased [22]. Inactivation
o ft h eM E N - 1g e n ec a u s e sc e l lt r a n s i t i o nf r o mG 0/G1 to S
phase and increases their proliferation [23]. Consequently,
overexpression of menin induces apoptosis. Loss of this
protein prevents apoptosis which normally occurs in cells
exposed to UV irradiation or TNF-α, and exogenous supple-
mentation of menin restores sensitivity to these stimuli [24].
Moreover, in vitro menin overexpression partially suppresses
tumour phenotype in neoplastic cell lines supporting its role
as a tumour suppressor [25, 26]. Up to now 459 diﬀerent
germline mutations have been reported in the literature and
recently summarized [27]. Most of the mutations identiﬁed
in MEN-1 subjects cause either absence or low availability
of menin [28, 29]. A complete loss of menin has been
described in tumours from patients with MEN-1 or from
mouse models of MEN-1 [30, 31].
A “two-hit” hypothesis is applied to describe the devel-
opment of tumours in MEN-1 [32]. In a germline carrier of
the mutated, nonfunctioning allele a tumour develops after
localinactivationoftheotherallele,allowingclonalinitiation
and promotion. Sporadic tumours may develop in a similar
mechanism as the two alleles are subsequently inactivated in
a cell line.
In line with this hypothesis in the sporadic cases of
parathyroid adenomas [33, 34], pancreatic [35, 36]a n d
anterior pituitary tumours [37, 38], as well as in carcinoids
of lung, thymus and stomach [39, 40], lipomas [38], and
skin tumours [41] loss of heterozygosity at the menin
locus has been described. Mutation of the MEN-1 gene
is the most predominant genetic aberration observed in
sporadic endocrine tumours. In approximately 20% of
sporadicparathyroidadenoma,gastrinoma,insulinoma,and
bronchial carcinoid an MEN-1 mutation can be found
[42, 43] .N oc o r r e l a t i o nb e t w e e nM E N - 1g e n o t y p ea n d
the tumour phenotype or aggressiveness has been found
[44], therefore MEN-1 sequencing is not useful for tumour
staging.
3. PrimaryHyperparathyroidisminMEN-1
Primary hyperparathyroidism (PHPT) is the most prevalent
clinical expression in MEN-1 mutation carriers, present
in more than 90% of cases (Table 1). Most frequently
multinodular hyperplasia of parathyroid glands is present;
however solitary tumours (usually diagnosed as adenomas)
have also been observed. Although the defective MEN-1
gene is a tumour suppressor, the parathyroid carcinoma
is diagnosed in the smaller proportion of patients than in
sporadic primary hyperparathyroidism. Mild hypercalcemia
with normal range serum PTH concentration can usually
be detected during the second decade of life [45]. Primary
hyperparathyroidism is a progressive disease in MEN-1.
Typically the MEN-1-associated parathyroid adenomas are
diagnosed at the age of about 25 years [46]—in a consid-
erably younger population compared to the sporadic cases,
occurring mainly about the ﬁfth decade of life [47].
A point to be mentioned is the high frequency of
supernumerary (up to 20%) and ectopic parathyroid glands,
usually localized within the thyroid gland, in the anterior
mediastinum and exceptionally in the pericardium in MEN-
1 patients [48]. Until now there is no evidence of parathyre-
matosis in MEN-1-associated PHPT.
The main clinical manifestation of MEN-1-associated
PHPT is progressing demineralisation [49] and/or recurrent
kidney stones [50, 51]. It was shown that 44% of patients
with uncontrolled MEN-1-associated PHPT had severe
osteopenia(Tscore,<–2.0)by35yearsofage[49].Recurrent
kidney stones are less frequently reported in MEN-1 families
[50, 51]. Unusually MEN-1 patients develop chronic kidney
disease in the course of nephrolithiasis, interstitial nephritis
and unrelated to the syndrome diabetes as the most frequent
cause of chronic kidney disease all over the world [51, 52].
4. Screeningfor Primary
HyperparathyroidisminMEN-1
It is recommended that biochemical screening for hyper-
parathyroidism, as well as for the other tumours, should
be performed every 1–3 years in the carriers of MEN-1International Journal of Endocrinology 3
Table 1: Tumours associated with MEN-1 and their penetrance.
Localization Clinical manifestation Penetrance
Endocrine
Parathyroid Primary hyperparathyroidism (bone demineralisation, kidney
stones)
90%
Enteropancreatic
Gastrinoma Zollinger-Ellison syndrome (severe peptic ulceration) 40%
Insulinoma Recurrent neuroglycopenia 10%
Nonfunctioning Late diagnosis (symptoms related to tumor mass) 20%
Other WDHA syndrome, diabetes mellitus 2%
Pituitary gland
Prolactinoma Galactorrhea, menstrual period anomalies, reduced libido,
erectile dysfunction, infertility
20%
Other Cushing syndrome, pituitary gland insuﬃciency 17%
Adrenal
Nonfunctioning cortex “Incidentaloma” 20%
Pheochromocytoma Paroxysmal or permanent arterial hypertension, paroxysmal
tachyarrhythmia, diabetes mellitus
<1%
Foregut neuroendocrine tumours
Gastric Carcinoid syndrome 10%
Thymic Carcinoid syndrome 2%
Bronchial Carcinoid syndrome, chronic cough 2%
Nonendocrine
Facial angioﬁbromas Local symptoms related to tumor mass 85%
Collagenomas Local symptoms related to tumor mass 70%
Lipomas Local symptoms related to tumor mass 30%
Leiomyomas Local symptoms related to tumor mass 10%
Meningiomas Intracranial pressure related symptoms 5%
Ependymomas Local symptoms related to tumor mass 1%
mutation. For a long period of time clinical manifestation is
mild,andthelackofregularscreeningmayresultinthedelay
of diagnosis and numerous complications [50].
Totalserumcalciumconcentrationcorrectedforalbumin
level or ionized calcium fraction has been considered the
single suﬃcient screening test for hyperparathyroidism in
MEN-1 [53], partly because identifying the earliest stages
of parathyroid growth has not been considered essential.
Recently, however, increased cardiovascular risk has been
observed in patients with mild hyperparathyroidism even
in the absence of hypercalcemia [54]. This may argue for
inclusion of serum PTH concentration measurement as a
screening test as well. Diagnosis of hyperparathyroidism
requires levels of PTH inadequately high for the parallel
calciumlevels.AtpresentdiﬀerentkitsforassessmentofPTH
are available. Second generation of kits, measuring concen-
trations of the so-called “intact PTH” (iPTH), are in the
general usage. These tests assess not only the concentration
1-84-PTH, but also of a truncated PTH fragment which was
deprived of the ﬁrst 1–6 N-terminal amino acids that do not
stimulate PTH receptor. Until now superiority of the third
generation of PTH kits, measuring only the concentration
of “native” 1-84-PTH, has not been proven for diagnosis of
primary hyperparathyroidism, at least in patients without
chronic kidney disease.
Routine testing for MEN-1 mutation in young patients
with primary hyperparathyroidism is not recommended, as
these mutations are rare in unselected patients even below
40 years of age [55]. The testing should be considered in
patients with additional risk factors such as multiple gland
disease, past history, or coexistence of other tumours charac-
teristic for MEN-1, family history of hyperparathyroidism or
MEN-1 tumours [56].
5.TreatmentofMEN-1Associated
Hyperparathyroidism
Total parathyroidectomy and thymectomy with autotrans-
plantation of parathyroid tissue is the therapy of choice
for primary hyperparathyroidism in MEN-1 in contrast
to single gland-resection in sporadic cases [57, 58]. The
surgeryinMEN-1-relatedhyperparathyroidism(HPT)bears
also more diﬃculties: postoperative hypoparathyroidism
and higher rates of recurrent or persistent HPT [57].
Recurrence is usually located in preserved parathyroid4 International Journal of Endocrinology
tissue—either a previously normal gland or a remnant
[59].Subtotalparathyroidectomyortotalparathyroidectomy
with thymectomy and autotransplantation is associated with
fewer recurrences than selective gland excision [60]. The
recurrence rate is strongly inﬂuenced by proceeding the
operation diagnosis of MEN-1, the surgeon’s experience,
and the possibility to perform an intraoperative histological
examination and quick PTH assessment [58]. The main role
of intraoperative PTH assessment is to conﬁrm the removal
of all the functional parathyroid tissue before parathyroid
autotransplantation.
It is not established if the guidelines for the asymp-
tomatic PHPT are applicable for MEN-1-associated PHPT.
Some experts advocate early parathyroidectomy to control
even mild hyperparathyroidism as uncontrolled disease is
associated with a progressive decline of bone mineral density
and the increased risk for kidney stones [61, 62]. In addition
Burgess emphasises education of the patient in respect to
hyperparathyroidism recurrence and possible reoperations
in the years to come [61].
Because malignancies in MEN-1 parathyroid tumours
are uncommon, pharmacological treatment is hypothetically
feasible. The development of calcimimetics brought a new
eﬀective, however expensive, and until now unlicensed
therapeutic option for both sporadic and MEN-1-associated
PHPT [63, 64]. Thus, such a therapy seems the only
option when surgery is not possible or has been ineﬀective.
Cinacalcet therapy is well tolerated by majority, but not all
patients. Gastrointestinal side eﬀects experienced by some
patients are followed by discontinuation of this therapy
[64]. Additionally calcimimetics have been shown to inhibit
parathyroid hyperplasia [65] so one may speculate that
they could slow the progression of parathyroid tumours in
MEN-1.
6. Conclusion
The diagnosis of MEN-1-associated primary hyperparathy-
roidism should be conﬁrmed by genetic testing. Carriers of
MEN-1 mutations require regular screening at least in 3-year
intervals regardless of the current presence of hyperparathy-
roidism from the second decade of life. Surgery remains the
main method of primary hyperparathyroidism management
despite of high recurrence rate and the necessity of repeated
procedures. Calcimimetic agents emerge as new therapeutic
option if surgery is not possible or has been ineﬀective.
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